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IL-17A mediates inflammatory and 
tissue remodelling events in early 
human tendinopathy
Neal L. Millar1, Moeed Akbar1, Abigail L. Campbell2, James H. Reilly1, Shauna C. Kerr1, 
Michael McLean1, Marina Frleta-Gilchrist1, Umberto G. Fazzi3, William J. Leach3, 
Brian P. Rooney3, Lindsay A. N. Crowe1, George A. C. Murrell4 & Iain B. McInnes1
Increasingly, inflammatory mediators are considered crucial to the onset and perpetuation of 
tendinopathy. We sought evidence of interleukin 17A (IL-17A) expression in early human tendinopathy 
and thereafter, explored mechanisms whereby IL-17A mediated inflammation and tissue remodeling in 
human tenocytes. Torn supraspinatus tendon (established pathology) and matched intact subscapularis 
tendon (representing ‘early pathology’) along with control biopsies were collected from patients 
undergoing shoulder surgery. Markers of inflammation and IL-17A were quantified by RT-PCR and 
immunohistochemistry. Human tendon cells were derived from hamstring tendon obtained during 
ACL reconstruction. In vitro effects of IL-17A upon tenocytes were measured using RT-PCR, multiplex 
cytokine assays, apoptotic proteomic profiling, immunohistochemistry and annexin V FACS staining. 
Increased expression of IL-17A was detected in ‘early tendinopathy’ compared to both matched 
samples and non-matched control samples (p < 0.01) by RT-PCR and immunostaining. Double 
immunofluoresence staining revealed IL-17A expression in leukocyte subsets including mast cells, 
macrophages and T cells. IL-17A treated tenocytes exhibited increased production of proinflammatory 
cytokines (p < 0.001), altered matrix regulation (p < 0.01) with increased Collagen type III and increased 
expression of several apoptosis related factors. We propose IL-17A as an inflammatory mediator within 
the early tendinopathy processes thus providing novel therapeutic approaches in the management of 
tendon disorders.
Overuse tendon injuries, namely tendinopathies, pose a significant clinical problem, particularly in musculo-
skeletal and sports related medicine1. The intrinsic pathogenetic mechanisms underlying the development of 
tendinopathies are largely unknown however proinflammatory mediators, such as cytokines, have recently been 
implicated functionally in several model systems2,3. In particular, the interaction between apoptosis and inflam-
mation is critical to tissue homeostasis and is known to play a key role in diseases such as rheumatoid arthritis4, 
neoplasia5, neurodegeneration6 and cardiovascular disease7.
Cytokines are critical in the response of soft tissues to injury and wound healing and have been shown to be 
involved in the regulation of matrix turnover in tendinopathy8. Endogenous expression of TNFα , IL-1β , IL-6, 
IL-10, VEGF and TGFβ has been demonstrated in tenocytes9–12. Such expression is functionally implicated 
in vivo: for example, the mechanical properties of healing tendons in IL-6−/− mice were inferior compared with 
littermate controls. Cytokines also play a key role in oxidative stress-induced cellular apoptosis13 which is medi-
ated by the activation of a variety of caspases. IFN-γ or TNF-α increased, whereas TGF-β or IL-10 decreased 
caspase 8 driven Fas mediated apoptosis in dermal fibroblasts14. IL-1β and TNF-α induce mitochondrial DNA 
damage, and mitochondrial transcription with subsequent induction of apoptosis in human chondrocytes15. By 
this means an inflammatory/apoptotic cascade of molecular events can promote tissue degeneration16.
Interleukin-17A, a member of the IL-17 family of cytokines is a pro-inflammatory mediator increasingly 
implicated in a variety of immune and inflammatory disease states. IL-17A expression is reported in several 
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cell types including Th17 cells17, γ δ T cells18 and some non lymphocyte lineages19; its receptor is ubiquitously 
expressed on many cell types, including myeloid cells, epithelial cells and fibroblasts20. IL-17A exerts various 
biological activities that could promote tissue destruction and degeneration during inflammation. In particular, 
it induces the production, often in a synergistic manner, of cytokines, including IL-1, IL-6, TNF-α , chemokines, 
inducible NO synthase, and matrix metalloproteinases (MMPs) by fibroblasts, macrophages, and endothelial 
cells21. Experimental models provide evidence for an early inflammatory response in tendinopathy2,22,23. Recently 
we have shown a distinct inflammatory infiltrate in early human tendinopathy24 and increased levels of proinflam-
matory cytokines including TNF-α , IL-6 in torn supraspinatus samples25. A recent transcriptomic analysis has 
highlighted increased expression of IL-17F in human tendinopathy biopsies26. Based on these observations and 
the plausible biological profile exhibited by IL-17A, we hypothesized that IL-17A may play a role in tendinopathy.
One of the major limitations of human studies is that tendon biopsies are usually obtained when patients are 
symptomatic and therefore biopsy material is likely to represent chronic, rather than early phase processes. We 
previously suggested that matched subscapularis tendon from patients with full thickness rotator cuff tears may 
be a model of early human tendinopathy based on histological appearances and significantly increased levels of 
cytokines and apoptotic markers in these tissues27. The purpose of this study was to formally assess the expression 
of IL-17A within this model and thereafter explore the mechanistic activities of IL-17A on inflammation, apop-
tosis and matrix production in tenocytes in vitro.
Methods
Human model of tendinopathy. All procedures and protocols were approved by the South East Area 
Sydney Area Ethics Committee (ACEC No. 99/101) and NHS West of Scotland Ethics Committee (REC 11/
S0704/7) with informed consent obtained and carried out in accordance standard operative procedures. Ten 
supraspinatus tendon samples were collected from patients with rotator cuff tears undergoing shoulder surgery 
(Table 1). The mean age of the rotator cuff ruptured patients was 54 years (range, 35–70 years) - the mean tear size 
was 2.5 cm2. Samples of the subscapularis tendon were also collected from the same patients. Patients were only 
included if there was no clinically detectable evidence of subscapularis tendinopathy on a preoperative MRI scan 
or macroscopic damage to the subscapularis tendon at the time of arthroscopy – by these criteria they represented 
a truly pre-clinical cohort. In this cohort all patients fulfilled the following criteria: 1) a history of shoulder pain 
and dysfunction, 2) no previous surgery on the affected shoulder, 3) no radiographic sign of fracture of the shoul-
der, and 4) no history of rheumatoid or osteoarthritis. An independent control group was obtained comprising 10 
samples of subscapularis tendon collected from patients undergoing arthroscopic surgery for shoulder stabiliza-
tion without rotator cuff tears, no previous shoulder surgery, no radiographic signs of shoulder fracture of history 
of rheumatoid or osteoarthritis. The absence of rotator cuff tears was confirmed by arthroscopic examination. The 
mean age of the control group was 35 years (range, 20–41 years).
Tissue collection and preparation. Arthroscopic repair of the rotator cuff was carried out using the 
standard three-portal technique while the cross-sectional size of the rotator cuff tear was estimated and recorded 
as previously described28. The subscapularis tendon was biopsied arthroscopically from the superior border of the 
tendon 1 cm lateral to the glenoid labrum representing mid body tendon structure. The supraspinatus tendon was 
harvested from within 1.5 cm of the edge of the tear prior to surgical repair. For immunohistochemical staining 
the tissue samples were immediately fixed in 10% (v/v) formalin for 4 to 6 hours and then embedded in paraffin. 
Sections were cut to 5 μ m thickness using a Leica-LM microtome (Leica Microsystems, Germany) and placed 
onto Superfrost Ultra Plus glass slides (Gerhard Menzel, Germany). The paraffin was removed from the tissue 
sections with xylene, rehydrated in graded alcohol and used for histological and immunohistochemical staining 
per previously established methodologies29.
Human tendon derived cells were explanted from hamstring tendon tissue of 5 patients (age 18–30 years) 
undergoing hamstring tendon ACL reconstruction. Cultures were maintained at 37 °C in a humidified atmos-
phere of 5% CO2 for 28 days. Cells were subcultured and trypsinized at subconfluency, with cells from the 3rd and 
4th passage utilised.
Histology and Immunohistochemistry techniques. Samples were stained with haematoxylin and 
eosin and toluidine blue for determination of the degree of tendinopathy as assessed by a modified version of the 
Bonar score30 (Grade 4 = marked tendinopathy, Grade 3 = advanced tendinopathy, 2 = moderate degeneration 
1 = mild degeneration 0 = normal tendon). This included the presence or absence of oedema and degeneration 
together with the degree of fibroblast cellularity and chondroid metaplasia. Thereafter, sections were stained 
with a range of primary monoclonal antibodies directed against the following markers: - IL-17A [using either 
Tear Size Control
Small 
(<1 cm2)
Medium 
(>1–3 cm2)
Large 
(>3–5 cm2)
Massive 
(>5 cm2)
Number of cases 10 3 3 2 2
Mean age in years(range) 32 (17–38) 54 (38–62) 55 (46–62) 52 (42–58) 60 (45–70)
Mean duration of symptoms in 
months (range) 6.0 (2–13) 8.8 (2–20) 6.3 (2–12) 9.8 (5–24) 7.3 (2–20)
Mean number of steroid injections 0 1.6 1.8 1.2 2.1
Table 1.  Patient demographics and rotator cuff tear size.
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goat anti-IL-17A polyclonal (R&D Systems, Abingdon, U.K) or mouse anti-IL-17A monoclonal (Cambridge 
Bioscience,UK), CD68, CD3, CD4, and mast cell tryptase (mast cells) (Vector Labs).
Endogenous peroxidase activity was quenched with 3% (v/v) H2O2, and nonspecific antibody binding blocked 
with 2.5% horse serum in TBST buffer for 30 minutes. Antigen retrieval was performed in 0.01 M citrate buffer for 
20 minutes in a microwave. Sections were incubated with primary antibody in 2.5% (w/v) horse serum/human 
serum/TBST at 4 °C overnight. After two washes, slides were incubated with Vector ImmPRESS Reagent kit as 
per manufactures instructions for 30 minutes. The slides were washed and incubated with Vector ImmPACT DAB 
chromagen solution for 2 minutes, followed by extensive washing. Finally the sections were counterstained with 
hematoxylin.
For double immunofluorscencent staining, ten paraffin embedded samples were incubated for 1 h with Abs 
(mouse anti-CD3 [1.25 μ g/ml; Vector Laboratories], mouse anti-CD4 [7.56 μ g/ml; Dako UK, Cambridgeshire, 
U.K.], mouse anti-mast cell tryptase [MCT] [0.43 μ g/ml; Dako UK], or mouse anti-CD68 [1 μ g/ml; Dako UK]) 
followed by 30 min incubation with biotinylated Abs (1:200; Vector Laboratories) with subsequent staining with 
streptavidin DyLight Fluor (1:500; Invitrogen, Paisley, U.K.) for 45 min. A second Avidin/Biotin blocking step 
(Avidin/Biotin Blocking Kit, Vector Labs) was carried out to prevent cross reactivity with the secondary antibody. 
Goat anti–IL-17A (5 μ g/ml) was added overnight at 4 °C, then incubated with a biotinylated Ab for 30 min, and 
stained with Avidin FITC (1:500; Vector Laboratories) for 45 min. Slides were mounted with Vectashield contain-
ing DAPI (Vector Laboratories) and analyzed on a fluorescent imaging microscope (BX50; Olympus, Essex, U.K.). 
Images were captured using Apple Open laboratory software. Positive (human tonsil tissue) control specimens 
were included, in addition to the surgical specimens for each individual antibody staining technique and double 
immunofluorescence staining. Omission of primary antibody and use of negative control (human osteoarthritis 
samples) isotypes confirmed the specificity of staining.
We applied a scoring system based on previous methods31 to quantify the immunohistochemical staining. Five 
random high power fields (x400) were evaluated by three independent assessors (NLM, JHR, ALC). In each field 
the number of positive and negatively stained cells were counted and the percentage of positive cells calculated 
giving the following semi-quantitative grading; Grade 0 = no staining, Grade 1 = <10% cells stained positive, 
2 = 10–20% cells stained positive, Grade 3 = >20% cells positive. Additional sub analysis of IL-17A + cells calcu-
lated the actual number of double stained cells were per high power field.
Apoptosis and Matrix Regulation. Cells were analysed using Annexin V binding, which detects transfer 
of phosphatidylserine to the outside of the membrane, cells were harvested with trypsin and stained with Annexin 
V-FITC Apoptosis Detection Kit (BD Pharmagen) for flow cytometer analysis. The production of thirty-five 
apoptotic related proteins in cell lysates were assessed using a proteome profiler (R&D systems) that contains 
capture and control antibodies spotted in duplicate on nitrocellulose membranes. The array is incubated with a 
cocktail of biotinylated detection antibodies.
Total soluble collagen was measured from cell culture supernatants using the Sircol assay kit (Biocolor Ltd, 
Carrickfergus, Northern Ireland) according to the manufacturer’s protocol. 1 ml of Sircol dye reagent was added 
to 100 μ l test sample and mixed for 30 min at room temperature. The collagen-dye complex was precipitated by 
centrifugation at 10,000 × g for 10 min; and then washed twice with 500 μ l of ethanol. The pellet was dissolved in 
500 μ l of alkali reagent. The absorbance was measured at 540 nm by microplate reader. The calibration curve was 
set up on the basis of collagen standard provided by the manufacturer. Additionally protein levels for Collagen 
I and III were quantified using pre coated ELISA plates (USCN Life Science Inc, Europe) with monoclonal anti-
bodies specific for human Collagen I and Collagen III and read at 450 nm by microplate reader after incubation 
with samples or collagen standards. The concentration of Collagen I and III in the samples was then calculated by 
comparing the optical density of the sample to the standard curve.
Signaling experiments. Phosphorylation status of mitogen-activated protein kinases (MAPKs), extra-
cellular signal regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNKs) and p38 isoforms were evaluated 
using the Human Phospho-MAPK Array (R&D Systems Europe, UK) as per the manufacturer’s instructions. 
The ERK inhibitor (FR180204) and Atk inhibitor (1L6-Hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-
3-O-octadecyl-sn-glycerocarbonate) were purchased from CalbioChem (Merck KGaA, Germany) and used at 
IC50 = 10 μ M, a concentration previously determined to offer optimal specific inhibition relative to off target effects.
RNA Extraction and Quantitative PCR. Tissue from 10 patients was available for RNA analysis and was 
placed in RNALater (Ambion) at the time of surgery. The cells isolated from in vitro experiments along with the 
available biopsy samples were placed in Trizol prior to mRNA extraction. QIAgen mini columns (Qiagen Ltd, 
Crawley UK) were used for the RNA clean-up with an incorporated on column DNAse step as per manufacturer’s 
instructions. cDNA was prepared from RNA samples according to AffinityScript™ (Agilent Technologies, CA, 
USA) multiple temperature cDNA synthesis kit as per manufactures instructions. SYBR green Real time PCR 
was performed using SYBR green mastermix (Applied Biosystems, CA, USA). Prior to setting up the SYBR green 
the cDNA was diluted 1 in 5 using RNase-free water. Each sample was analysed in triplicate. Primers (Integrated 
DNA Technologies, Belgium) were as follows: GAPDH, 5′-TCG ACA GTC AGC CGC ATC TTC TTT-3′ (F) and 
5′-ACC AAA TCC GTT GAC TCC GAC CTT-3′ (R), COL1A, 5′- CAA TGC TGC CCT TTC TGC TCC TTT-3′ 
(F) and 5′-CAC TTG GGT GTT TGA GCA TTG CCT-3′ (R), COL 3A, 5′- TAT CGA ACA CGC AAG GCT GTG 
AGA-3′ (F) and 5′-GGC CAA CGT CCA CAC CAA ATT CTT-3′ (R), MMP 13, 5′- AAG GAC CCT GGA GCA 
CTC ATG TTT-3′ (F) and 5′-TGG CAT CAA GGG ATA AGG AAG GGT-3′ (R), CASPASE 3, 5′-TCA TTA TTC 
AGG CCT GCC GTG GTA (F) and 5′-TGG ATG AAC CAG GAG CCA TCC TTT-3′, CASPASE 7, 5′-TTC CTC 
TTC GCC TAT TCC ACG GTT (F) and 5′-ATT CAC CCT GGT GAG GAT CTG CAT-3′ (R), Smac, 5′ GCG 
CGG ATC CAT GGC GGC TCT GAA GAG TTG (F) and 5′ AGC TCT CTA GAC TCA GGC CCT CAA TCC 
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TCA (R), IL-17A, 5′-AGG CCA TAG TGA AGG CAG GAA TCA-3′ (F) and 5′- ATT CCA AGG TGA GGT GGA 
TCG GTT-3′ (R).
Cytokine production. A 25-Plex human cytokine assay evaluated the in vitro quantitative determination of 
25 separate human cytokines using Luminex technology. Supernatants (n = 5, in triplicate) were removed from 
cell culture and analyzed for cytokine production.
Statistical analysis. Results are reported as mean values ± SD. ANOVA followed by Tukey’s test or Student’s 
t test was applied to in vitro studies. Analysis between individual in vitro groups was examined by ANOVA fol-
lowed by the Student-Newman-Keuls test or Student’s t test using Graphpad Prism, version 6.0 (Graphpad Inc, 
CA). A value of p < 0.05 was considered to be significant.
Ethical approval information. All procedures and protocols were approved by the South East Area Sydney. 
Area Ethics Committee (ACEC No. 99/101) and NHS West of Scotland Ethics Committee (REC 11/S0704/7) with 
informed consent obtained and carried out in accordance standard operative procedures.
Data Availability. NLM has access to all the data and data are available upon request.
Figure 1. IL-17A expression in human tendinopathy samples. (A) Graphs illustrate modified Bonar scoring for 
samples of human tendon biopsies for expression of CD3, CD68 and MCT markers with mean and SEM shown. 
n = 10 for control tendon, n = 10 for torn tendon and early tendinopathy. Modified Bonar scoring system depicts 
mean score per sample based on 10 high power fields. 0 = no staining, 1 = < 10% , 2 = 10–20%, 3 = > 20% + ve  
staining of cells per high power field. * p < 0.05, ** p < 0.01 (Students t-test) (B) IL-17A gene expression in 
tendon samples. Delta Ct values of IL-17A in control (n = 10, intact subscapularis biopsy), torn tendon (torn 
supraspinatus biopsy) and early tendinopathy ( matched intact subscapularis biopsy) human tendon samples 
(n = 10). Data are mean ± SD relative to house keeping gene18S (mean of duplicate analysis). * p < 0.05, ** p < 0.01 
(Students t-test). (C) Quantitative expression of CD3 + /IL-17+ , CD68 + /IL17+ and MCT/IL-17+ depicts 
mean cells per sample based on 10 high power fields. n = 10 for control tendon, n = 10 for torn tendon and early 
tendinopathy * p < 0.05, ** p < 0.01 versus control tissue, (Students t-test).
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Results
Early tendinopathy shows increased IL-17A expression. Staining for cell markers of macrophages, 
mast cells and T cells was significantly greater in subscapularis compared to both matched torn supraspina-
tus biopsies and control tissues (Fig. 1A), confirming that our early tendon lesions contained an inflammatory 
infiltrate. Subscapularis tendon biopsies exhibited significantly (p < 0.01) greater IL-17A mRNA levels than did 
biopsies from torn supraspinatus or control tendon (Fig. 1B). We also observed increased tissue staining for 
IL-17A. To characterise these IL-17A+ cells in human tendinopathy, we performed colocalisation studies and 
calculated the proportion of IL-17A+ cells contained in each cellular subset. We first investigated T cell markers, 
namely, CD3, CD4, that colocalised with IL-17A (Fig. 1C). Although some CD3+ IL-17A+ cells were identified, 
the majority of IL-17A+ cells were CD3-negative. Approximately 1% of IL-17A expressing cells expressed CD3 
by IHC. CD4 cells were limited in number throughout the samples and we identified no co-expression of IL-17A, 
presumably reflecting this low sample size. Up to 20% of IL-17A+ cells were CD68+ (Fig. 1C and Supplementary 
Fig. 1A). The majority of IL-17A+ cells double-stained with MCT, suggesting that mast cells represent a lineage in 
which IL-17A protein expression is enriched in human tendinopathy (Figs 1C and 2A,C). As a further control, we 
used both goat polyclonal and mouse monoclonal anti-human IL-17A antibodies and obtained essentially similar 
staining patterns in tissue (Fig. 2B).
The inflammatory cell infiltrate correlated inversely (r = 0.4, p < 0.01) to rotator cuff tear size in the torn 
supraspinatus biopsies with larger tears showing significantly fewer inflammatory cell types. No significant asso-
ciations were noted between IL-17A expression and the age of patients, duration of symptoms or number of prior 
steroid injections. All torn supraspinatus samples showed Grade 4 changes consistent with marked degenera-
tion, mucoid change and frank chondroid metaplasia. Matched subscapularis tendon showed Grade 2–3 changes 
indicative of moderate-advanced tendinopathy. All control samples were classified as Grade 1 consistent with 
normal fibrotendinous tissue with large distinct collagen fibrils. There were no significant correlations between 
Bonar score and the mean duration of symptoms or age of the patient cohort.
IL-17A alters tenocyte collagen synthesis. Since type III collagen expression is a dominant feature of 
tendinopathy, as compared with type I collagen, we next considered whether IL-17A might alter differential 
collagen synthesis by tenocytes utilising a previously characterized in vitro system31. rhIL-17A (using dose/time 
points optimization derived in preliminary experiments) significantly elevated total collagen production by teno-
cytes (Fig. 3A) at 24 hours (mean 300 μ g/ml ± 62 control; 590 μ g ± 71 IL-17A) and 48 hours (712 μ g ± 82 control; 
Figure 2. IL-17A localisation in tendon samples. (A) Early human tendinopathy sample (matched 
subscapularis tendon biopsy) stained for (A) Mast cell tryptase (MCT) and IL-17A , Isotype IgG in bottom 
left corner using goat polyclonal IL-17A antibody. (B) Early tendinopathy sample stained for IL-17A using 
mouse monoclonal antibody and goat polyclonal antibody. Isotype IgG in bottom left corner. (C) Double 
imunofluorescence staining using goat polyclonal IL-17A antibody showing IL-17A, Mast Cell Tryptase and 
double staining co-localization in early tendinopathy sample. (x100).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:27149 | DOI: 10.1038/srep27149
1200 μ g ± 92 IL-17A). Collagen 1A mRNA levels were unchanged at 6, 12 and 48 hours whereas in contrast, 
Collagen 3A mRNA was significantly up-regulated at 24 & 48 hours by rhIL-17A compared to controls (Fig. 3B). 
This was confirmed at the protein level showing a significant increase in collagen III production at 24 hours 
(mean 10.2 η g/ml ± 3 control; 32.4 η g ± 5 100 η g rhIL-17) and 48 hours (mean 16.4 η g ± 4 control; 45.5 η g ± 7 
100 η g rhIL-17) post treatment with rhIL-17A (Fig. 3C).
IL-17A promotes cytokine production in tenocytes. We next explored the extent to which IL-17A 
could regulate the local cytokine milieu via modulating tenocyte behaviour. IL-17RA expression was confirmed 
in both patient biopsy samples and cultured human tenocytes (Supplementary Figure 1B). rhIL-17A (using 
dose/time points optimization derived in preliminary experiments) significantly elevated production of TNF-α 
, MIP1α , IL-6, IL-8 and MCP-1 (Fig. 3D). In contrast, we found no production over time of a range of other 
cytokines including IL-4, IL-5, IL-10, IL-12, IL-13, and IL-15, consistent with our expectations of the known 
cellular sources of such cytokine production.
IL-17A induces apoptosis in tenocytes in vitro. Based on previous observations of dysregulated apop-
tosis in tendinopathy31 and that of IL-17A induced apoptosis in other musculoskeletal disorders we examined 
the effect of rhIL-17A in our model system in vitro. Addition of 100 ng of rhIL-17A to human tenocyte cultures 
significantly increased the number of cells undergoing apoptosis assessed by Annenix V staining at 24 hours 
(control mean 5 ± 2%, IL-17A mean 48 ± 10%) and 48 hours (control 8 ± 4%, IL-17A 50 ± 15%) (Fig. 4A,B). 
Based on our previous observations concerning cell death in early tendinopathy, we utilised limited proteomic 
profiling to assess which apoptotic mediators may be regulated by IL-17A. This revealed over expression of pro 
and cleaved caspase 3, heat shock proteins (HSP) 27, 70 and second mitochondria-derived activator of caspases 
(Smac) (p < 0.01) after 24 hours treatment with 100 ng rhIL-17A. (Fig. 4C and Supplementary Fig. 1C). This was 
Figure 3. The effect of IL-17A on collagen matrix production. (A) Total collagen production assessed using 
Sircol assay. Data represents mean collagen production (μ g/ml) ± SD in control and rhIL-17A(100 ng) treated 
normal hamstring tenocyte cultures over a 48 hour time course. * p < 0.05, ** p < 0.01 compared to control 
samples.(Students t-test) (B) The levels of mRNA for Collagen type IA and Collagen type IIIA were determined 
by real time PCR over a 48 hour time (100 ng rhIL-17A). Data shown as the mean ± SD of triplicate samples and 
represent experiments on five individual normal hamstring tendon patient explant samples utilising GAPDH 
housekeeping versus control. * p < 0.05, ** p < 0.01 (Students t-test) (C) Collagen I and III protein expression 
24 hours post incubation in control versus 50/100 ng rhIL-17A conditions. Data are shown as the mean ± SD of 
triplicate samples and are in turn, representative of experiments performed on three individual normal hamstring 
tendon patient explants. * p < 0.05, ** p < 0.01 compared to control samples (Students t-test). (D) Cultured normal 
hamstring tenocytes were incubated with recombinant IL-17A (100 ng) over 24 hours. Data shown represent 
levels of MCP-1, TNF-α , IL-8 , IL-6 and MIP-1α in supernatants removed from culture at 24 hrs analysed 
using Luminex. Data shown are the mean ± SD of triplicate samples and are representative of five individual 
experiments * p < 0.05, ** p < 0.01 (ANOVA).
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confirmed at the mRNA level by quantitative PCR that revealed elevated expression of caspase 3, HSP 27, HSP 70 
and Smac (p < 0.05) in tenocytes (Fig. 4D).
MAP Kinases mediate some of the effects of IL-17A in tenocytes. We next addressed potential 
signal pathways mediating these effects based on previous reports of MAPK signaling by IL-17A32. Tenocytes 
cultured with rhIL-17A exhibited increased phosphorylation of ERK 1, ERK 2 and Atk 1 & 2 (Fig. 5A and supple-
mentary Figure 1D). To explore the functional consequences of these observations, we employed ERK and Atk 
inhibitors in our tenocyte cultures. We observed significant reduction in production of MCP-1, IL-6, and IL-8 
with both ERK and Atk inhibition, while TNF-α production was reduced by ERK inhibition and not Atk inhi-
bition. No change was noted in MIP-1α production by either inhibitor (Fig. 5D). Interestingly, we observed no 
significant change in total collagen production, collagen I and III mRNA or protein levels in IL-17A treated teno-
cytes with ERK or Atk inhibition suggesting that other pathways may regulate those events (Fig. 5B). Additionally 
ERK and Atk inhibition resulted in a significant increase in HSP 27 and 70 gene expression with no associated 
changes in caspase 3, or Smac (Fig. 5D) suggesting that ERK/Atk pathways may be involved in modulating the 
specific pathways implicated in cell death.
Discussion
Our study provides evidence that IL-17A could operate as a cytokine modulator of early tendinopathy. Herein we 
demonstrate that IL-17A is present in early tendinopathy biopsies and thereafter in mechanistic studies demon-
strate that IL-17 likely contributes to regulation of inflammatory and apoptotic pathways in tendon cells, associ-
ated with a change in collagen matrix synthesis.
Figure 4. Apoptosis and IL-17A. Apoptosis was evaluated after 24 h of (A) control conditions (no cytokines) 
and rhIL-17A stimulation (100 ng). Flow cytometry profile represents Annexin V-FITC staining in x axis and 
7-AAD in y axis. (B) Time course showing percentage of apoptotic cells over a 48 hour time course under 
control (no cytokines) and 10 ng/20 ng/50 ng/100 ng rh IL-17A conditions. Data shown as the mean ± SD of 
triplicate samples and are in turn, representative of experiments performed on three normal hamstring tendon 
patient explants. * p < 0.05, ** p < 0.01 compared to control samples (ANOVA). (C) Whole cell lysates from 
control and rhIL-17 (100 ng) conditions (24 hours incubation) were harvested and apoptotic markers evaluated 
using an apoptotic proteome profiler. The fold change of apoptotic proteins was determined by densitometry 
and normalised to the control sample on the array at 24 hours. * p < 0.05, ** p < 0.01 compared to control 
samples (Students t-test). (D) The levels of mRNA for the highlighted apoptotic markers were determined by 
real time PCR under the same conditions (100 ng rh IL-17A at 24 hours). Data are shown as the mean fold 
change ± SD of duplicate samples and are representative of experiments using five individual donors of normal 
hamstring tendon explant tissue * p < 0.05, ** p < 0.01 compared to control samples (Students t-test).
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Experimental models provide good evidence of an early inflammatory response in tendinopathy. A running 
rodent model of tendinopathy is associated with upregulation of key inflammatory modulators including the 
5-lipoxygenase activating protein (FLAP) and cyclo-oxygenase2 at early and intermediate time points. In rabbit 
and equine models excessive mechanical load promotes acute inflammatory cell infiltration22,23. Our data demon-
strate in human tendinopathy that IL-17A is upregulated and thereafter capable of inducing other inflammatory 
cytokines that may ultimately disturb the balance between reparative and degenerative processes in the extracel-
lular matrix. In particular increased levels of IL-6 and IL-8, which have previously been shown to effect matrix 
metalloproteinases production in fibroblasts33, will likely mediate downstream effects on tenocyte collagen matrix 
production. Thus the IL-17 cytokine family may provide a molecular link between the initiation and perpetuation 
of the inflammatory cascade in tendon biology (Fig. 6C). This may not be restricted to IL-17A - increased IL-17F 
expression from human tendinopathic biopsies is also reported26.
We and others have highlighted the key role of infiltrating leukocytes in human tendon disease24,34,35. The 
exact cellular source of IL-17A remains uncertain in the context of human inflammatory lesions as compared to 
disease models36,37. Many human biopsy studies suggest IL-17A expression in varied cellular lineages. Whereas 
lymphoid lineages, particularly T cells and innate lymphocytes are clearly primary IL-17A sources, it is possible 
that mast cells37, macrophages38 or neutrophils39 can also contribute to the local cytokine pool, either by synthesis, 
or by receptor mediated uptake and subsequent release. Regardless of the precise cellular synthetic source, our 
data add growing credence to the notion that immune cells are an early source of IL-17A in response to stress and 
injury19. Investigations in renal fibrosis reveal a role for IL-17RA as a novel modulator of monocyte phenotype 
and polarisation towards tissue macrophages and thus potentially tissue remodelling40. Strategies to interfere with 
Figure 5. IL-17A induced phosphorylation of MAPK in cultured tenocytes and matrix response to ERK 
and Atk inhibition. (A) Whole-cell lysates from tenocytes were examined for the expression of phosphorylated 
ERK1, ERK2, Atk1 and Atk2 24 hours after exposure to 100 ng rhIL-17A The fold change of MAPK’s was 
determined by densitometry and normalised to the control sample on the array. Data are shown as the mean 
fold change ± SD of duplicate samples and are representative of experiments using three individual donors of 
normal hamstring tendon explant tissue. * p < 0.05, ** p < 0.01 compared to control samples (ANOVA). (B) Cells 
were preincubated for 24 h with specific inhibitors for ERK (FR 180204)(10 μ M), or Atk(5 μ M) which also were 
included in the assay media. Total collagen production was assessed using the Sircol assay * p < 0.05, ** p < 0.01 
(Students t-test). (C) The levels of apoptotic proteins induced following incubation with ERK and Atk inhibitors 
were determined (apoptotic proteome profiler) by densitometry and normalised to the relevant control sample 
on the array. Data are shown as the mean fold change ± SD of duplicate samples and are representative of 
experiments using five individual donors of normal hamstring tendon explant tissue * p < 0.05, ** p < 0.01 
(ANOVA). (D) Cells were preincubated for 24 h with 100 ng recombinant IL-17A and specific inhibitors for 
ERK (FR 180204) and Atk, which also were included assay media. Data shows levels of MCP-1, IL-8, IL-6, TNF-
α and MIP-1α in supernatants removed from culture analysed using Luminex. Data shown are the mean ± SD 
of triplicate samples and are representative of five normal hamstring tendon explant experiments * p < 0.05,  
** p < 0.01 (Students t-test).
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IL-17A signaling and the ability of ERK/Atk inhibitors to reduce IL-17A associated effector function therefore 
may provide novel therapeutics in human tendinopathy.
Approximately 95% of collagen in normal tendon is type I; type III is present in small amounts. Biopsies from 
normal and ruptured Achilles tendon demonstrate that ruptured tendons contained reduced quantities of type 
I collagen as a well as a significant proportion of type III collagen41. The presence of type III collagen accounts 
for the decreased resistance of tendon to tensile forces and subsequent rupture42. Here we show that IL-17A not 
only increased total collagen production but apparently shifted production towards collagen III compared to 
type I. By this route, IL-17A may cause detrimental phenotypical changes in the tendon extracellular matrix. This 
idea is supported by recent investigations in scleroderma patients showing decreased collagen I expression in 
IL-17A treated fibroblasts43. Inhibition of ERK/Atk signaling had no effect on IL-17 induced matrix production 
suggesting an alternative pathway is implicated in this facet of IL-17A effector function. Further investigation is 
required to understand the signaling biology of IL-17A on collagen synthesis and thus fully appreciate optimal 
translational targets.
Excessive apoptosis has been postulated as a primary cause of tendinopathies44. The apoptotic cells in the 
rotator cuff have been identified as fibroblasts or fibroblast ‘like’ which are, in turn, key regulators of tendon 
extracellular matrix16, however the regulation of apoptosis in tendinopathy is poorly understood. Several fac-
tors, including mechanical overuse45, hypoxia46 and oxidative stress47 are thought to contribute to pathogenesis. 
We have previously shown increased expression of pro-apoptotic genes in a rodent overuse models and in torn 
human supraspinatus tendons compared to controls27. Our study now reveals that addition of IL-17A to normal 
tenocyte cultures causes overexpression of caspases molecules known for their ‘death’ role in apoptosis48 at both 
the protein and mRNA level supporting the concept of IL-17A as a further regulator of apoptosis. This reflects 
in vitro findings in osteoarthritis fibroblasts where addition of rhIL-17A promotes apoptosis49. However we note 
that in RA synviocytes rhIL-17A mediates pro survival mechanisms via Bcl-250. Thus further mechanistic work 
in diseased tenocytes may be required to determine the hierarchical and discrete kinetic roles of IL-17A mediated 
apoptosis in early versus late tendinopathy.
We also reveal significant changes in several additional regulators of the mitochondrial pathway of apoptosis. 
HSP 27 indirectly interferes with cell death due to its ability to modulate intracellular glutathione, a parameter 
that is also regulated by exercise, while HSP 70 interacts with Apaf-1 thereby preventing its interaction with the 
caspases preventing apoptosis49,51. Smac binds to inhibitor of apoptosis proteins (IAPs) and deactivates them, 
preventing the IAPs from suppressing caspase activity52. We have previously suggested heat shock proteins as 
modulators of apoptosis in early tendinopathy27 and our mechanistic studies are commensurate with this notion.
There are limitations inherent in our study. Age-related changes within the tendon samples could contribute to 
the degenerative picture and inflammatory cell expression seen in the matched subscapularis tendons. However 
the lack of degenerative change on MRI and arthroscopic examinations suggests that the differences are truly at 
the cellular level as suggested by our work. Subscapularis tendon is functionally and organizationally distinct 
from supraspinatus and thus responds to mechanical loading in a different manner that may alter its cellular 
profile. Control samples from subscapularis undergoing stabilisation may not be truly ‘normal’ controls but are 
currently the best available control tendon sample and this is reflected by a Bonar score of 1. It is reassuring 
however that we found the same inflammatory cell subtypes in matched subscapularis tissue indicating that the 
Figure 6. The role of IL-17A in inflammatory mechanisms in tendinopathy. Schematic diagram illustrating 
the manner in which early tendinopathy may arise due to IL-17A induction. An increase stress that a tendon cell 
experiences results in the release of various inflammatory mediators such as IL-17A that interact to drive the 
tendon matrix toward a degenerative of reparative process.
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inflammatory response may be uniform within joints subjected to tendon degeneration. In addition having sub-
scapularis samples from the same patient eliminates bias that may result from variation between individuals and 
has been previously shown to be useful method in sampling of tissues. We point out also that while our human 
tissue biopsies show presence of IL-17A at mRNA and protein levels, the majority of our mechanistic work utilises 
an early disease in-vitro culture system and that further mechanistic investigation in an in-vivo tendon model 
and late disease in vitro cultures would more likely address the hierarchal role of IL-17A in tendon remodelling.
Conclusion
On the basis of these results we propose IL-17A as an inflammatory regulator in tendon remodeling - better 
understanding of the pathological cascade that it induces should lead to the development of cell targeted treat-
ment modalities for early human tendinopathy.
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